Schizophrenia Research
Volume 81, Issue 1 , Pages 1-15 , 1 January 2006

One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia

  • Richard S.E. Keefe

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC 27710, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 919 684 4306; fax: +1 919 684 2632.
    • ,
  • Carrie A. Young

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN US 46285, United States
    • ,
  • Stephanie L. Rock

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN US 46285, United States
    • ,
  • Scot E. Purdon

      Affiliations

    • Department of Psychiatry, University of Alberta, CHA-ANE, Box 307, Edmonton, Alberta, Canada T5J 2J7
    • ,
  • James M. Gold

      Affiliations

    • Maryland Psychiatric Research Center, University of Maryland Baltimore, School of Medicine, P.O. Box 21247, Baltimore, MD 21228, USA
    • ,
  • Alan Breier

      Affiliations

    • Lilly Research Laboratories, Indianapolis, IN US 46285, United States
    • ,
  • HGGN Study Group

      Affiliations

    • Consisted of all authors and others, who participated in the design and execution of HGGN study partially funded by Lilly Research Laboratories.

Received 21 February 2005 ,Revised 27 July 2005 ,Accepted 29 July 2005.

References 

  1. Awas AG, Voruganti LN. Quality of life and new antipsychotics in schizophrenia. Are patients better off?. Int. J. Social Psychiatry. 1999;45:268–275
  2. Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. Antipsychotic medication effects on neuropsychological functions. Psychopharm. Bull. 1992;28:353–366
  3. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry. 2000;157:549–559
  4. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry. 2002;159:1018–1028
  5. Braff DL, Heaton R, Kuck J, Cullum M, Moranville J, Grant I, et al. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Arch. Gen. Psychiatry. 1991;48:891–898
  6. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 1994;36:717–725
  7. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr. Bull. 1994;20:31–46
  8. Crawford JR, Steward LE, Moore JW. Demonstration of savings on the AVLT and development of a parallel form. J. Clin. Exp. Neuropsychol. 1989;11:975–981
  9. Cuesta MJ, Peralta V, Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr. Res. 2001;48:17–28
  10. Daniel DG. Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders. Biol. Psychiatry. 1994;35:667
  11. Erlenmeyer-Kimling L, Cornblatt B. Attentional measures in a study of children at high-risk for schizophrenia. J. Psychiatr. Res. 1978;14:93–98
  12. Gallhofer B, Lis S, Meyer-Lindenberg A, Krieger S. Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr. Scand. 1999;395:118–128
  13. Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch. Gen. Psychiatry. 1990;47:1066–1072
  14. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 1993;162:43–48
  15. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  16. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am. J. Psychiatry. 1997;154:799–804
  17. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr. Bull. 2000;26:119–136
  18. Green MF, Marder SR, Glynn SM, McGurk SR, Wirshing WC, Wirshing DA, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol. Psychiatry. 2002;51:972–978
  19. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised, Publication ADM 76 338 ed.. Bethesda, Md: US Department of Health, Education, and Welfare; 1976;
  20. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 1993;34:702–712
  21. Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implications of atypical neuroleptic treatment. CNS Spectr. 1997;2:1–11
  22. Harvey PD, Keefe RSE. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry. 2001;158:176–184
  23. Harvey PD, Howanitz E, Parrella M, White L, Davidson M, Mohs RC, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am. J. Psychiatry. 1998;155:1080–1086
  24. Harvey, P.D., Davidson M., DeSmedt G., et al. 2003 Treatment of cognitive impairments in early psychosis with risperidone vs. low dose haloperidol. Presented at the International Congress on Schizophrenia Research, Colorado Springs.
  25. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr. Res. 2004;66:101–113
  26. Heaton RK. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources; 1993;
  27. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–444
  28. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am. J. Psychiatry. 1992;149:898–903
  29. Hoff AL, Harris D, Faustman WO, Beal M, DeVilliers D, Mone RD, et al. A neuropsychological study of early onset schizophrenia. Schizophr. Res. 1996;20:21–28
  30. Javitt DC, Doneshka P, Grochowski S, Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch. Gen. Psychiatry. 1995;52:550–558
  31. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  32. Keefe RSE, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 1999;25:201–222
  33. Keefe RSE, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: A randomized double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry. 2004;161:985–995
  34. Keilp JG, Herrera J, Stritzke P, Cornblatt BA. The continuous performance test, identical pairs version (CPT-IP): III. Brain functioning during performance of numbers and shapes subtasks. Psychiatry Res. 1997;74:35–45
  35. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 1994;55:82–87
  36. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999;25:233–255
  37. Meyers JE, Meyers KR. Rey complex figure test under four different administration procedures. Clin. Neuropsychol. 1995;9:63–67
  38. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 1979;134:382–389
  39. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol. Rep. 1962;10:799-81
  40. Park S, Holzman PS, Goldman-Rakic PS. Spatial working memory deficits in the relatives of schizophrenic patients. Arch. Gen. Psychiatry. 1995;52:821–828
  41. Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry. 2000;57:249–258
  42. Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 2001;26:137–149
  43. Ritsner M, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur. Neuropsychopharma. 2002;12:31–38
  44. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F, et al. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 1997;95:40–43
  45. Sax KW, Strakowski SM, Keck PE, McElroy SL, West SA, Stanton SP. Symptom following affective correlates of attentional improvement hospitalization for a first episode of psychosis. Biol. Psychiatry. 1998;44:784–786
  46. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry. 1991;48:618–624
  47. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naïve patients with first-episode schizophrenia. Arch. Gen. Psychiatry. 1994;51:124–131
  48. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Second Edition. New York: Oxford University Press; 1998;
  49. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Can. J. Psychiatry. 1996;41:S35–S40
  50. Strauss WH, Klieser E. Cognitive disturbances in neuroleptic therapy. Acta Psychiatr. Scand., Suppl. 1990;358:56–57
  51. Uiterwaal CS, Grobbee DE, Witteman JC, van Stiphout WA, Krauss XH, Havekes LM, et al. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann. Intern. Med. 1994;121:576–583
  52. Vakil E, Blachstein H. Rey auditory-verbal learning test: structure analysis. J. Clin. Psychol. 1993;49:883–890
  53. Velligan DI, Bow-Thomas CC. Executive function in schizophrenia. Semin. Clin. Neuropsychiatry. 1999;4:24–33
  54. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 1997;25:21–31
  55. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia?. J. Ner. Mental Dis. 2000;188:518–524
  56. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin RK, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr. Res. 2002;53:239–248
  57. WAIS-III . WMS-III Technical Manual. San Antonio, Tx: The Psychological Corporation; 1997;(Harcourt Brace and Company)
  58. Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale—Revised. New York, NY: The Psychological Corporation; 1981;(Harcourt Brace and Company)
  59. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharma. 2005;8:457–472

☆ Colleogium Internationale Neuro-Psychopharmacologicum annual meeting June 23–27, 2002; Montreal, Canada; European College on Neuropsychpharmacology annual meeting October 5–9, 2002; Barcelona, Spain; American College Of Neuropsychopharmacology annual meeting December 8–12, 2002; San Juan, Puerto Rico; International Congress on Schizophrenia Research annual meeting March 29–April 2, 2003; Colorado Springs, CO, USA.

PII: S0920-9964(05)00355-5

doi: 10.1016/j.schres.2005.07.038

Schizophrenia Research
Volume 81, Issue 1 , Pages 1-15 , 1 January 2006

Article Tools

* Image Usage & Resolution